Velcade Is Superior Over Dexamethasone For Myeloma

Exposure to prior myeloma therapies, specifically thalidomide (Thalomid) and autologous stem cell transplants (ASCT), does not influence the superior efficacy of Velcade (bortezomib) compared to dexamethasone (Decadron) in patients with relapsed/refractory myeloma, according to an analysis published in the British Journal of Haematology.

continue reading

Myeloma: Genetics And Treatment History As Prognostic Factor

A new study published in the journal Leukemia determined that when treated with Revlimid (lenalidomide) and dexamethasone (Decadron), relapsed and refractory myeloma patients with genetic risk factors experience lower response rates and shorter progression-free and overall survival durations.

continue reading

Velcade-Doxil-Dexamethasone Regimen For Multiple Myeloma

A combination regimen of Velcade (bortezomib), Doxil (pegylated liposomal doxorubicin), and dexamethasone (Decadron), known as the VDD regimen, followed by Revlimid (lenalidomide) after autologous stem cell transplantation (ASCT) is an effective therapy for untreated multiple myeloma patients.

continue reading

What asthma preventers are available?

Corticosteroids: There are many corticosteroids around, such as beclomethasone, fluticasone, dexamethasone and prednisolone. They are often in brown-coloured inhalers, and are marketed with names such as Becotide, Flixotide and Pulmicort. Corticosteroids (or ’steroids’) have made an enormous difference to the management of asthma.

continue reading

NICE Recommends Revlimid Be Covered For Multiple Myeloma

On April 23, the UK National Institute for Health and Clinical Excellence (NICE) announced its final decision to recommend coverage of Revlimid (lenalidomide), in combination with dexamethasone (Decadron), for multiple myeloma patients who have already received prior therapies.

continue reading

Survival Rate Comparison for Elderly Myeloma Patients

Article reports on results of a clinical trial published in April issue of the journal Blood. The trial found that eldery multiple myeloma patients treated with the thalidomide-dexamethasone regimen had a lower survival rate than patients treated with the melphalan-prednisone regimen.

continue reading

Exciting Multiple Myeloma Data at ASH

Updated results from the ECOG study evaluating Revlimid plus low-dose dexamethasone in newly diagnosed patients was presented by Dr. Rajkumar in a joint symposium of the American Society of Clinical Oncology and ASH. The results are the highest 3 year overall survival rates ever reported in this patient group.

continue reading

Obesity Linked to Reduced Steroid Response in Asthmatics

The cellular response to dexamethasone is reduced in overweight/obese patients with asthma relative to their lean counterparts, according to a report in the first October issue of the American Journal of Respiratory and Critical Care Medicine.

continue reading

Corticosteroids in dogs and cats

Corticosteroids are the most widely used immunosuppressants in dogs and cats. Two drugs are frequently used: prednisone (or prednisolone), and dexamethasone. Prednisone is used for both induction and maintenance, whereas dexamethasone is typically used in the induction phase, and only brieftly.

continue reading

IV dexamethasone helpful in treating acute migraine

A randomized, double blind study published in the journal Neurology indicates that intravenous administration of the steroid dexamethasone to migraineurs in the emergency department is effective in relieving their pain.

continue reading